Kids Safe and Smokefree (KiSS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study's primary aim is to test the hypothesis that an intervention integrating pediatric clinic-level quality improvement with home-level behavioral counseling (CQI+BC) will result in greater reductions in child cotinine (a biomarker of secondhand smoke exposure) and reported cigarettes exposed/day than a clinic-level quality improvement plus attention control intervention (CQI+A). A secondary aim is to test the hypothesis that relative to CQI+A, CQI+BC will result in higher cotinine-verified, 7-day point prevalence quit rate among parents.
| Condition | Intervention |
|---|---|
|
Tobacco Smoke Pollution Nicotine Dependence |
Behavioral: Clinic Quality Improvement + Behavioral Counseling (CQI+BC) Behavioral: Clinic Quality Improvement + Attention Control (CQI+A) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Pediatrician Advice, Family Counseling & SHS Reduction for Underserved Children |
- Child urine cotinine [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]Child urine cotinine is a biomarker for assessing second-hand smoke exposure. We anticipate the CQI+BC treatment group will experience a greater reduction in child urine cotinine over time than the CQI+A control group.
- Parent-reported second-hand smoke exposure in cigarettes per day [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]Parental report of cigarettes child is exposed to each day in the home and car by all sources during the 7 days prior to assessment. We anticipate the CQI+BC treatment group will report greater reductions in second-hand smoke exposure over time than the CQI+A control group.
- Parent-reported cotinine-verified 7-day point prevalence abstinence [ Time Frame: 7 days prior to 12 week and 12 month assessments ] [ Designated as safety issue: Yes ]When a participant reports smoking abstinence, we will bioverify their smoking status.
| Estimated Enrollment: | 350 |
| Study Start Date: | March 2012 |
| Estimated Study Completion Date: | February 2017 |
| Estimated Primary Completion Date: | February 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Clinic Quality Improvement + Behavioral Counseling (CQI+BC)
This multilevel intervention includes advice and a referral from a pediatrician, behavioral counseling by study staff, and community systems navigation, all designed to reduce pediatric secondhand smoke exposure. Over the course of 12 weeks participants receive a home visit designed to orient them to the program and trained health counselors provide multiple individualized phone counseling sessions designed to build coping skills, urge management skills, and self-efficacy. Counseling also includes assistance with goal setting and navigation of local resources.
|
Behavioral: Clinic Quality Improvement + Behavioral Counseling (CQI+BC) |
|
Active Comparator: Clinic Quality Improvement + Attention Control (CQI+A)
The attention control intervention parallels the format of the CQI+BC group but focuses on family nutrition information. The intervention includes a home visit to orient the participant to the program and multiple phone counseling sessions conducted by a trained health counselor.
|
Behavioral: Clinic Quality Improvement + Attention Control (CQI+A) |
Detailed Description:
Child secondhand smoke exposure (SHSe) is a significant public health problem that has been linked to asthma, acute respiratory illnesses, otitis, and SIDS, and is associated with increased risk of cancers, cardiovascular disease, and behavior problems. This project will test the effectiveness of a comprehensive multilevel intervention to reduce young children's SHSe in minority and medically underserved communities known to have the highest SHSe-related morbidity and mortality risk. First, we will provide a clinic-level quality improvement (CQI) intervention to improve the care of pediatric patients with SHSe in four pediatric clinics in North and West Philadelphia. We will then randomize eligible parents visiting the CQI clinics into either a home-level behavioral counseling intervention (CQI+BC) or a home-level attention control intervention (CQI+A). In addition to clinic-level intervention, CQI+BC provides personalized, behavioral counseling with intensive skills training and support where SHSe occurs (in the home), as well as systems navigation to facilitate access to and effective use of reimbursable nicotine replacement therapy and smoking cessation medication. Participants will complete assessments at pre-treatment, 3-month end of treatment, and 12-month follow-up.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- at least 18 years of age
- English-speaking
- parent or legal guardian of child under 11 years old who lives with him/her
- daily smoker
Exclusion Criteria:
- non-nicotine drug dependence
- psychiatric disturbance (bipolar, schizophrenia, psychosis)
- pregnant
- inadequate health literacy
Contacts and Locations| Contact: Brad Collins, PhD | 215-204-2849 | collinsb@temple.edu |
| Contact: Melissa Godfrey, MPH | 215-204-0315 | melissa.godfrey@temple.edu |
| United States, Pennsylvania | |
| Temple University | Recruiting |
| Philadelphia, Pennsylvania, United States, 19122 | |
| Contact: Brad Collins, PhD 215-204-2849 | |
| Principal Investigator: Brad Collins, PhD | |
| Principal Investigator: Stephen Lepore, PhD | |
| St. Christopher's Hospital for Children | Recruiting |
| Philadelphia, Pennsylvania, United States, 19134 | |
| Contact: Daniel Taylor, MD 215-817-1149 daniel.taylor@drexelmed.edu | |
| Sub-Investigator: Daniel Taylor, MD | |
| Children's Hospital of Philadephia | Active, not recruiting |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Temple University Hospital System | Recruiting |
| Philadelphia, Pennsylvania, United States, 19140 | |
| Contact: Beth Moughan, MD 251-370-7556 beth.moughan@tuhs.temple.edu | |
| Sub-Investigator: Beth Moughan, MD | |
| Principal Investigator: | Brad Collins, PhD | Temple University |
| Principal Investigator: | Stephen Lepore, PhD | Temple University |
More Information
No publications provided
| Responsible Party: | Temple University |
| ClinicalTrials.gov Identifier: | NCT01745393 History of Changes |
| Other Study ID Numbers: | R01CA158361 |
| Study First Received: | November 12, 2012 |
| Last Updated: | December 7, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Temple University:
|
Smoking Cessation Secondhand Smoke Passive Smoking Cotinine Nicotine Replacement Products |
Additional relevant MeSH terms:
|
Tobacco Use Disorder Substance-Related Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 21, 2013